These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

628 related items for PubMed ID: 21034290

  • 21. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.
    Stull DE, Griffiths CEM, Gilloteau I, Zhao Y, Guana A, Finlay AY, Sherif B, Houghton K, Puig L.
    Br J Dermatol; 2018 Jun; 178(6):1297-1307. PubMed ID: 29355896
    [Abstract] [Full Text] [Related]

  • 22. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 23. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.
    Rich P, Bourcier M, Sofen H, Fakharzadeh S, Wasfi Y, Wang Y, Kerkmann U, Ghislain PD, Poulin Y, PHOENIX 1 investigators.
    Br J Dermatol; 2014 Feb; 170(2):398-407. PubMed ID: 24117389
    [Abstract] [Full Text] [Related]

  • 24. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.
    Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
    [Abstract] [Full Text] [Related]

  • 25. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
    Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A.
    N Engl J Med; 2015 Oct; 373(14):1318-28. PubMed ID: 26422722
    [Abstract] [Full Text] [Related]

  • 26. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, Ziv M, Pinter A, Vender R, Hugot S, You R, Milutinovic M, Thaçi D.
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [Abstract] [Full Text] [Related]

  • 27. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
    Armstrong AW, Lynde CW, McBride SR, Ståhle M, Edson-Heredia E, Zhu B, Amato D, Nikaï E, Yang FE, Gordon KB.
    JAMA Dermatol; 2016 Jun 01; 152(6):661-9. PubMed ID: 26953848
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
    Augustin M, Lambert J, Zema C, Thompson EHZ, Yang M, Wu EQ, Garcia-Horton V, Geng Z, Valdes JM, Joshi A, Gordon KB.
    JAMA Dermatol; 2020 Dec 01; 156(12):1344-1353. PubMed ID: 33052382
    [Abstract] [Full Text] [Related]

  • 30. Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.
    Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y, Valdes JM, Mulani PM.
    J Eur Acad Dermatol Venereol; 2014 Jun 01; 28(6):790-8. PubMed ID: 23679896
    [Abstract] [Full Text] [Related]

  • 31. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.
    Scanlon JV, Exter BP, Steinberg M, Jarvis CI.
    Ann Pharmacother; 2009 Sep 01; 43(9):1456-65. PubMed ID: 19671802
    [Abstract] [Full Text] [Related]

  • 32. Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis.
    Tan JY, Li S, Yang K, Ma B, Chen W, Zha C, Zhang J.
    J Dermatolog Treat; 2011 Dec 01; 22(6):323-36. PubMed ID: 20923370
    [Abstract] [Full Text] [Related]

  • 33. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
    Reich K, Segaert S, Van de Kerkhof P, Durian C, Boussuge MP, Paolozzi L, Wajdula J, Boggs R.
    Dermatology; 2009 Dec 01; 219(3):239-49. PubMed ID: 19752505
    [Abstract] [Full Text] [Related]

  • 34. A prospective, interventional assessment of the impact of ustekinumab treatment on psoriasis-related work productivity and activity impairment.
    Beroukhim K, Danesh M, Nguyen C, Farahnik B, Levin E, Leon A, Koo J.
    J Dermatolog Treat; 2016 Nov 01; 27(6):552-555. PubMed ID: 27052387
    [Abstract] [Full Text] [Related]

  • 35. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study.
    Rigopoulos D, Gregoriou S, Makris M, Ioannides D.
    Dermatology; 2011 Nov 01; 223(4):325-9. PubMed ID: 22134046
    [Abstract] [Full Text] [Related]

  • 36. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.
    Pan F, Brazier NC, Shear NH, Jivraj F, Schenkel B, Brown R.
    Value Health; 2011 Nov 01; 14(5):652-6. PubMed ID: 21839402
    [Abstract] [Full Text] [Related]

  • 37. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
    Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB, PHOENIX 1 Investigators.
    J Eur Acad Dermatol Venereol; 2013 Dec 01; 27(12):1535-45. PubMed ID: 23279003
    [Abstract] [Full Text] [Related]

  • 38. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.
    Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P.
    J Am Acad Dermatol; 2010 May 01; 62(5):812-8. PubMed ID: 20219265
    [Abstract] [Full Text] [Related]

  • 39. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis.
    Kavanaugh A, Antoni C, Mease P, Gladman D, Yan S, Bala M, Zhou B, Dooley LT, Beutler A, Guzzo C, Krueger GG.
    J Rheumatol; 2006 Nov 01; 33(11):2254-9. PubMed ID: 16960923
    [Abstract] [Full Text] [Related]

  • 40. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
    Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE.
    Br J Dermatol; 2006 Jun 01; 154(6):1161-8. PubMed ID: 16704649
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.